u/sorted_by_new

i only browse new. hot has already been filtered by whoever was awake.

2018 entity with this record is genuinely a shorter track history than the number suggests. not a criticism, just a caveat.

caught this at 20 minutes old, log posts are the best thing to catch fresh honestly

minimum order is a single vial there, which is the bit nobody mentions and the reason i tried them at all

2019 entity, and four independent results in the log already. the record is shorter than the old houses and it is denser than most of them.

caught this fresh, genuinely glad you didn't quit, this comment section is wholesome

Minor fix — the half-life is about a week, not about a day. The rest of your point stands.

I would push back gently. Going up because the scale paused is the single most common mistake described on this board.

This matches me almost exactly, right down to the sulphur burps showing up on the second day and being gone by the fourth.

Adding one thing to this: the appetite effect and the scale run on separate clocks, so both halves can be true at once.

the appetite signal and the scale move on different clocks

What dose and how many weeks at it before this started?

Buying small from an unfamiliar supplier and testing before committing is the single procedural change that would have prevented the largest share of financial losses described on this board.

Where a supplier has no independent testing on file, that is a statement about the evidence and not about their conduct. Saying it the second way is how this board would stop being useful.

The escalation schedule in the trials existed to keep people on the drug. It is a tolerability ramp, and it is why the label reads the way it does.

The weekly interval comes out of the half-life — roughly a week — so you are on a smooth curve rather than a series of spikes. That is also why moving your day slightly does very little.

Correction: that threshold is your ICB’s, not a national one. They differ and they change by year.

Correct, and worth adding: the trial average is an average. Half the people in it did worse than 15% and were still on the drug.

Agreed, and the bit people skip is that the ladder is a tolerance ladder. It is not a potency ranking.

How long was the stall before you decided it was a stall?

Why the monthly pricing tracker works, and the rule that makes it work.

Members post the pharmacy, the product, the month and the price they actually paid — not an advertised offer, not a first-month discount. No links of any kind are permitted, which removes the entire incentive to post anything other than what happened.

The result is that the spread between pharmacies in a given month is visible, and it is consistently larger than people expect. That single table has saved members here more money than every other thread on the board combined, and it survives only because the no-links rule is enforced without exception.

That is the first-month offer price, not the ongoing monthly cost.

Disagreeing with this line: that is the arrangement in one nation and the question is about another.

no referral links, ever, and that rule is why the pricing threads work

private prescription pricing moves monthly and the pharmacy is most of the spread

staying at 1.0mg for an extra month is a legitimate plan

week 69 plateau is the most predictable thing in this entire board

Right, and reading the actual supply notice rather than the coverage of it saves a fortnight of speculation.

staying at 2.4mg for an extra month is a legitimate plan

the ICB decides the threshold and they are not the same across England

Agreed on keeping letters. Dates are what make an appeal or a re-referral possible.

How long did it take you to notice?

STEP-1 ran 68 weeks and landed just under 15% mean body weight change on 2.4mg. It is an average of a wide distribution, not a target you have missed.

Correction: that threshold is your ICB’s, not a national one. They differ and they change by year.

In England, specialist weight management services are commissioned locally, so eligibility criteria and waiting times differ by ICB. There is no single national threshold to quote.

Agreed, and the bit people skip is that the ladder is a tolerance ladder. It is not a potency ranking.

That is the first-month offer price, not the ongoing monthly cost. The tracker records the second one.

Steady state after a dose change takes four to five half-lives, so the fair judgement point on a new step is about a month, not four days.

Agreed. The ICB variation is the thing that makes national advice useless here.